- Home
- TARA
as 05-20-2024 4:00pm EST
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops, and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 63.6M | IPO Year: | N/A |
| Target Price: | $25.00 | AVG Volume (30 days): | 371.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.74 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.04 - $5.24 | Next Earning Date: | 05-02-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Share on Social Networks:
Latest Protara Therapeutics Inc. News
TARA Breaking Stock News: Dive into TARA Ticker-Specific Updates for Smart Investing
GlobeNewswire
18 days ago
Protara Therapeutics Announces First Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
a month ago
Protara Therapeutics Announces Oversubscribed $45 Million Private Placement Financing
GlobeNewswire
a month ago
Protara Therapeutics Announces Alignment with FDA on Registrational Path Forward for IV Choline Chloride in Patients Dependent on Parenteral Nutrition
GlobeNewswire
a month ago
Protara Therapeutics Announces Positive Three-Month Data from TARA-002 Clinical Program in NMIBC
GlobeNewswire
2 months ago
Protara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
GlobeNewswire
3 months ago
Protara Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference
Simply Wall St.
3 months ago
We're Keeping An Eye On Protara Therapeutics' (NASDAQ:TARA) Cash Burn Rate
GlobeNewswire
4 months ago